Johannes Kratz

Title: **Johannes Kratz: A Pioneer in Lung Cancer Prognostics**

Introduction

Johannes Kratz is an innovative inventor based in Cambridge, MA, known for his significant contributions to the field of lung cancer research. With a focus on improving prognosis methods, Kratz has worked diligently to advance medical practices that can impact patient outcomes.

Latest Patents

Kratz holds a patent for a "Multigene prognostic assay for lung cancer." This groundbreaking invention offers methods to determine the prognosis for lung cancer by utilizing a panel of eleven molecular markers, including BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and WNT3A. These markers are differentially expressed in lung cancer and are pivotal in predicting overall survival outcomes over a five-year period, particularly in non-squamous non-small cell lung cancer (NSCLC).

Career Highlights

Throughout his career, Johannes Kratz has collaborated with esteemed institutions that have supported his research endeavors. Notably, he has been affiliated with the University of California and Encore Clinical, Inc. These experiences have greatly contributed to his expertise and innovations in the field.

Collaborations

Kratz has had the privilege of working alongside prominent researchers such as Michael Mann and David Jablons. These partnerships have enabled the pooling of knowledge and resources, enhancing the quality and impact of their research on lung cancer prognosis.

Conclusion

Johannes Kratz stands as a testament to the importance of innovation in the medical field. His patent on a multigene prognostic assay represents a significant leap forward in the management of lung cancer, potentially improving outcomes for countless patients. As the landscape of cancer research continues to evolve, inventors like Kratz play a crucial role in shaping the future of diagnostics and treatment.